Stock Financial Ratios

CFCO / CF Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price9.88
Volume302,400.00
Market Cap ($M)223.41
Enterprise Value ($M)167.87
Book Value ($M)5.00
Book Value / Share0.33
Price / Book165.98
NCAV ($M)-45.22
NCAV / Share46.08
Price / NCAV-12.68
Income Statement (mra) ($M)
Revenue0.00
EBITDA0.00
Net Income0.00
Balance Sheet (mrq) ($M)
Cash & Equivalents0.48
Cash / Share0.03
Assets0.00
Liabilities71.29
Quick Ratio1.41
Current Ratio1.41
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.00
Return on Assets (ROA)0.00
Return on Equity (ROE)0.00
Identifiers and Descriptors
CUSIPG20307107
Central Index Key (CIK)1668428
Industry Groups
Share Statistics
Common Shares Outstanding269,000,000
Common Shares Outstanding15,000,000
Temporary Equity Shares Outstanding64,066,643
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Treasury Stock Per Share0.00
Liabilities Current Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Cash And Equivalents Per Share0.03
Assets Current Per Share0.39
Cash Per Share0.03
Liabilities Per Share4.75

Related News Stories

CF Industries Holdings' (CF) CEO Anthony Will on Q4 2017 Results - Earnings Call Transcript

2018-02-15 seekingalpha
CF Industries Holdings, Inc. (NYSE:CF) Q4 2017 Earnings Conference Call February 15, 2018 9:00 AM ET (33-0)

Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

2018-02-13 zacks
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) announced that the FDA has granted approval to its cystic fibrosis (CF) corrector, tezacaftor (VX-661), in combination with ivacaftor (Kalydeco) under the brand name, Symdekotm. The combo therapy is approved to treat the underlying cause of CF in patients aged 12 years and above with certain mutations in the CF transmembrane conductance regulator gene. (52-0)

Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why

2018-01-25 zacks
Vertex Pharmaceuticals, Inc. (VRTX - Free Report) shares are up 70.1% in the past year, comparing favorably with an increase of 9.6% for the industry. (82-0)

BRIEF-CF Corp intends to transfer listing of its ordinary shares and warrants to New York Stock Exchange​

2017-11-20 reuters
* CF corp - ‍CF Corp intends to transfer listing of its ordinary shares and warrants to New York Stock Exchange​ Source text for Eikon: Further company coverage: (16-1)

Vertex Gets CHMP Recommendation for Orkambi Label Expansion

2017-11-13 zacks
Vertex Pharmaceuticals Inc. (VRTX - Free Report) announced that the Committee for Medicinal Products for Human Use ("CHMP") has recommended approval of a label expansion for Orkambi in Europe. The company is seeking extension of its marketing authorization for Orkambi to include use in children with cystic fibrosis ("CF") who are aged between 6 and 11 years and have two copies of the F508del mutation. (63-1)

CUSIP: G20307107